by David Brindley | Dec 18, 2012
Some words have the ability to induce instant and unexplained anxiety. In developing industries, such as cell therapy, one such example is regulation – of any sort. Crudely, our negative perception of regulation can be attributed to two factors: an aversion to both...
by Michael May | Nov 19, 2012
James Till and Ernest McCulloch identified stem cells 50 years ago in Toronto, and their legacy is a vibrant community of scientists who are leaders in this field of research. But what does that mean in terms of producing products and therapies to heal and cure...
by David Brindley | Nov 5, 2012
Recently, in the twilight on a balmy summer’s evening in DC, an irrationally passionate cell therapy war room convened over meze, ouzo and retsina. And considered the meaty question posed by Lonza’s Jon Rowley: “Where do you think you and the cell therapy industry...
by Stacey Johnson | Sep 26, 2012
My grandmother, at 97, is excited about stem cell research because she sees the possibilities. Regenerative medicine IS an exciting field. It’s on the cutting edge of science and fans and critics alike debate its merits regularly in the press and in blogs. Every day,...
by Natasha Davie | Aug 16, 2012
The health-care landscape is changing: the previous model of the blockbuster pharmaceutical is being challenged by new therapies that have the potential to offer more effective treatments. In this new contribution to Signals Blog, I describe the present landscape for...
by Paul Krzyzanowski | Jul 17, 2012
Faced with patent shortages to replace flagship products, Big Pharma is increasing investments in smaller biotech companies to capture innovations early. Most new companies wither and die if they run out of initial funds before they’re profitable. In biotech,...
Comments